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al-antitrypsin (AAT) deficiency is an inherited condition characterized by low serum levels of AAT and an increased 
risk of developing pulmonary emphysema. The disease occurs mainly in Caucasians, but Southern Europe, including 
Italy, is considered a low prevalence area. We developed a national program in Italy in order to improve our 
knowledge of the epidemiology of AAT deficiency and to establish a registry of the AAT-deficient individuals. The 
program had two phases: the first lasted 36 months, during which blood from coupons mailed by respiratory 
physicians from throughout the country, was isoelectrofocused by the Central Laboratory in Rome. The second 
phase started in February 1996, and the Registry was established. Up to August 1998, 151 subjects with AAT 
deficiency have been identified and 64 have been enrolled in the Registry. We believe that such a program plays a 
crucial role in identifying AAT deficiency in a country such as Italy, with low prevalence and low awareness of this 
rare condition. 
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Introduction 
al-antitrypsin (AAT) deficiency is an inherited disorder 
characterized by low serum levels of AAT, and predispos- 
ing to the early development of pulmonary emphysema, 
particularly in individuals who smoke. The condition was 
first described in 1963 by Laurel1 and Eriksson (1) and since 
then major advances have been made in understanding the 
biochemical basis and world-wide epidemiology of the 
disease. AAT is a 52-kDa glycoprotein produced mainly 
by hepatocytes and its primary function is to inhibit 
neutrophil elastase. It is coded for by a gene spanning 
12.2 kb located on chromosome 14q32.1, in which a 
number of mutations account for the high pleomorphism of 
the protein,. Normal serum levels of AAT range from 
150-350 mg dl ~ ’ (20-53 ,uM), and they are associated with 
alleles referred to as M, based on their position of migration 
on isoelectric focusing. The increased risk of developing 
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pulmonary emphysema is associated with alleles coding for 
AAT levels 4 80 mg dl - ’ (I 11 ,uM), the commonest being 
referred to as Z. Other deficient variants conferring 
increased risk are those associated with the Null alleles, 
which contribute no AAT to the serum concentration and, 
to a lesser extent, the S allele, which confers a significant 
risk only in smokers and in heterozygosity with Z or Null 
alleles (2,3). 
AAT deficiency occurs mainly in Caucasians, with a 
frequency similar. to that of cystic fibrosis in North 
America and Europe (4). The Z allele frequency in 
Northern Europeans and in Northern Americans is esti- 
mated to be between 0.03 and 0.01 (incidence 
1: 1600 3500 - I). Southern Europe is considered to be a 
low prevalence area for AAT deficiency (5,6). In Italy, 
for example, up to the early 1990s the condition was 
diagnosed so rarely that single new cases were frequently 
reported in the national scientific journals (7). However, 
based on studies performed in the late 1970s and in the 
early 1980s in the general population or in newborns in 
selected zones of the country (8), prevalence of type ZZ 
homozygotes, at least in northern Italy, seems to be not 
dissimilar from that reported for northern Europe and 
America, with an average prevalence of 1:3500 inhabi- 
tants. A decreasing north to south gradient has been 
reported, the prevalence ranging from 1:3500 to 1:5000 in 
central Italy and from 1:5000 to 1:lO 000 in southern Italy 
and in the islands (Sicily and Sardinia) (9-11). 
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TABLE 1. Results of the screening program 
Total period First phase 
(January 1993- (January 1993- 
August 1998) January 1996) 
Second phase 
(February 1996 
August 1998) 
Subjects screened (n) 1841 859 982 
Reason for screening (%) 
Disease (%) 14 78 71 
Family screening (%) 26 22 28 
AAT-deficient subjects identified (n) 151 70 81 
Identification rate (%) 12.1 12.2 12.1 
Monthly identification rate 2.3 1.9 2.9 
Defective phenotypes 
zz 118 56 62 
SZ 17 7 10 
Null Null 8 3 5 
Z Null 4 2 2 
Rare variants 4 2 2 
In order to address the discrepancy between expected and 
actual diagnosed cases of AAT deficiency in Italy, a nation- 
wide program to detect the condition was established in 
1993. This paper describes the structure, methods and 
results of the program. 
Material and Methods 
ORGANIZATION AND PHASES OF THE 
PROGRAM 
The program resulted from a working group, composed of 
members from the two major Italian respiratory societies, 
AIPO (Associazione Italiana Pneumologi Ospedalieri) and 
SIMeR (Societa Italiana di Medicina Respiratoria). The 
resulting program was named IDA, an acronym of Identi- 
ficazione Deficit Alfal-antitripsina (AAT deficiency identi- 
fication). The aims of the program were: 1. to establish, by 
means of an exploratory phase lasting for 3 years (January 
1993-January 1996), the feasibility of a nationwide survey 
to detect AAT deficiency in Italy, and 2. to establish, by 
means of a second, more structured phase beginning in 
February 1996, a registry of subjects with severe AAT 
deficiency. 
During the first, exploratory phase, coupons with dried 
spots of blood on blotting paper together with a brief 
questionnaire were distributed to respiratory physicians at 
University- and community-based hospitals and clinics 
throughout the country. Screening was recommended for 
individuals with a missing or reduced al-globulin band on 
serum protein electrophoresis or a plasma AAT level 
4 80 mg dl - ‘, patients with early onset emphysema and 
familial cluster of COPD, and first-degree relatives of 
subjects with ascertained AAT deficiency or carrying MZ 
heterozygosity. The coupons and questionnaires were then 
mailed to the Central Phenotyping Laboratory in Rome, 
where they were processed (see below). Data were collected 
and reviewed by an ad hoc committee of the working group. 
Before and during this phase, the program was promoted 
during national and local meetings. 
After careful examination of the final results of the first 
phase, the working group decided to proceed towards the 
second phase. The flow chart described for the first phase 
was modified as follows: the result of the phenotyping, 
included within the questionnaire (screening form) attached 
to the coupons, are collected by a National Coordinating 
Center and transferred to a database. In the meantime, 
the National Coordinating Center informs the referring 
physicians of the result of phenotyping. In the case of a 
deficient phenotype, the physician is asked to fill in a more 
detailed questionnaire (enrolment form) or, alternatively, to 
send the patient to the nearest of 30 Regional Reference 
Centers, which then proceeds to enrol the patient. 
The enrolment form contains the following data: demo- 
graphic details, smoking habit, reason for phenotyping, 
diagnosis, concomitant diseases, history and physical 
examination findings, serum AAT level, pulmonary func- 
tion test and blood gas analysis, liver function, chest X-ray 
and high resolution CT scan (if available). Enrolment form 
data are then collected by the National Coordinating 
Center and transferred to a database. 
PI PHENOTYPING 
PI phenotyping was carried out using dried blood speci- 
mens absorbed on special paper. Specimens were mailed 
and processed as described (12). Positive and inconclusive 
cases were asked for a sample of serum and PI typing 
was repeated twice with reference samples for ease of 
comparison (13). 
Results 
During the entire period of the program, 1841 samples 
overall were mailed to the Central Phenotyping Laboratory 
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in Rome and a total of 151 subjects with AAT deficiency 
were detected. During the 36 months of the first phase of 
the program, screening of 859 samples allowed the identi- 
fication of 70 subjects with AAT deficiency, of which 56 
(80%) carried the ZZ phenotype. During the first 30 months 
of the second phase of the program (data updated to 
August 1998) 982 further subjects were screened. A total of 
81 AAT-defective subjects were identified, of which 61 
(75%) carried the ZZ phenotype. Results of the screening 
program are summarized in Table 1. 
In agreement with the previously reported north-to-south 
gradient, over 90% of AAT-defective subjects are located in 
northern Italy. However, the ratios of samples submitted 
and AAT-deficient subjects identified showed the following 
results: 7.2 for northern Italy, 35.6 for central Italy, and 21 
for southern Italy and the islands. This would suggest that 
the rate of detection reflects not only the above-mentioned 
gradient, but also a poorer adherence to the screening 
guidelines offered by physicians in the central and southern 
regions. 
So far, 64 subjects with AAT deficiency have completed 
the enrolment process and have therefore been included in 
the Italian Registry for AAT deficiency. Table 2 reports the 
characteristics of those patients, divided into index cases 
(i.e. the propositus subjects, identified for medical reasons 
or during population screening) and non-index cases (i.e. 
relatives of a propositus, identified during the family 
screening). 
Discussion 
TABLE 2. Characteristics of enrollees in the Italian Registry 
for AAT deficiency 
Index Non-index 
cases cases 
(n=50) (n= 14) 
Female/male 
Phenotype 
zz 
sz 
Z Null 
Null Null 
M ma~ton/Moristano 
Mean age (years) 
Smoking 
Never 
Former 
Current 
Diagnosis 
Old 
Healthy 
EPD 
Mean AAT level (mg dl - ‘) 
Lung function (OLD) 
FEV, 
FVC 
Lung function (healthy + EPD) 
FEV, 
FVC 
21129 
43 
3 
1 o/4 
10 
1 
2 
51 f 13 48& 14 
14 6 
29 2 
I 6 
43 
2 
33* 18 37.4 f 19 
44 It 22% 51 f 17% 
76 z!z 26% 86 zk 25% 
115 Yt 13% 120 f 20% 
116f 10% 118f21% 
As is the case for other rare conditions, the only way to 
improve our knowledge of AAT deficiency is to gather 
information from as many cases as possible. Such a strategy 
has succeeded in North America with the identification of 
1129 AAT-deficient subjects, who were enrolled into a 
registry whose goal it was to characterize the natural 
history of AAT deficiency, irrespective of augmentation 
therapy (14). Other large populations of AAT-deficient 
subjects have been enrolled into national registries in 
Sweden, Germany, The Netherlands and Denmark, all 
countries with a high prevalence of the condition (4). 
The primary goal of our program was to study the 
feasibility of an AAT registry in Italy. Due to the low 
prevalence of this condition in Italy, especially in the central 
and southern areas, and the concomitant low awareness 
among respiratory physicians, it seemed necessary to start 
with an exploratory phase. This phase was designed with 
the primary goal of making physicians aware of the 
problem. In spite of the low rate of identified subjects 
(Table l), the considerable effort made produced satisfac- 
tory cooperation from physicians and in the meantime 70 
individuals with AAT deficiency were identified. During the 
first 30 months of the second phase, 81 further AAT 
deficient subjects were identified, with a slight improvement 
in the monthly identification rate (Table 1). Meanwhile, the 
encouraging results of the first phase prompted us to 
establish a registry of AAT-deficient subjects, enrolling 
individuals identified in both the first and second phases of 
OLD, obstructive lung disease (emphysema, chronic 
bronchitis, COPD or bronchiectasis). 
EPD, extra-pulmonary disease (liver disease in 3, sinusitis 
in 2). 
the program. As expected, the vast majority of index cases 
(48/50) were referred for medical reasons, either pulmonary 
or extrapulmonary. Among non-index cases, which were 
ascertained during family screening, the percentage of iden- 
tification was 28% among siblings and 13% among children. 
Seven out of the 14 non-index cases were completely 
healthy (Table 2). Such a result, which has been previously 
reported in larger European surveys, represents one of the 
major issues related to AAT deficiency (15) that many 
individuals with AAT deficiency do not have clinically 
significant lung function impairment. Indeed, although the 
sample size of our series is limited so far, it seems clear that 
a substantial group of AAT-deficient subjects have well- 
preserved lung function (Table 2) and that the other 
important risk co-factor, smoking, is not a mandatory 
prerequisite for developing airflow obstruction. In other 
words, the relationship between genotype and the resulting 
phenotype in AAT deficiency is not yet completely eluci- 
dated (16). As the enrolment process proceeds, the Italian 
Registry for AAT deficiency will become a crucial tool not 
only for understanding the epidemiology of this condition 
in our country, but also for a better understanding of the 
clinical course of the disease in the light of other risk 
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factors. In addition, the establishment of the registry will be 
useful in designing clinical trials (4). Replacement therapy 
with plasma-purified AAT has been very recently licensed 
by Italian authorities; the registry will also serve as a means 
to collect data about patients on replacement therapy. 
In conclusion, we have described the organization 
and results of a national program developed in Italy to 
detect AAT-deficient individuals. We have succeeded in the 
identification of a large series of AAT-deficient subjects in 
Italy, and in the establishment of a registry. We believe that 
a nationwide program is crucial in detecting AAT 
deficiency in a country such as Italy, where the disease has 
a low prevalence and, as a consequence, low awareness 
among respiratory physicians. 
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